XERS

Business Context and Reporting Period

Xeris Biopharma Holdings, Inc. (XERS) is a growth-oriented biopharmaceutical company commercializing three products: Gvoke (glucagon for severe hypoglycemia), Recorlev (cortisol synthesis inhibitor for Cushing's syndrome), and Keveyis (treatment for Primary Periodic Paralysis). The company also maintains a pipeline, including XP-8121 (once-weekly subcutaneous levothyroxine). This summary covers the quarterly period ended September 30, 2024.

Key Financial Metrics

Liquidity: As of September 30, 2024, the company held $59.2 million in cash and cash equivalents and $10.2 million in short-term investments. Management believes current resources are sufficient to sustain operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 12.3% in Q3 2024 and 19.6% for the nine months ended September 30, 2024, compared to the prior year periods.
• Product Performance:
  • Recorlev: Net revenue surged 118.9% in Q3 and 111.0% for the nine months, driven by significant volume growth.
  • Gvoke: Net revenue increased 29.4% in Q3 and 23.1% for the nine months, driven by prescription growth.
  • Keveyis: Net revenue declined 23.1% in Q3 and 10.1% for the nine months due to lower volume.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 20.6% in Q3 and 13.7% for the nine months, primarily due to CEO succession/restructuring costs ($6.1 million) and Recorlev expansion efforts. Cost of goods sold (COGS) increased 65.7% in Q3, partly due to a $3.6 million write-off of Gvoke components related to manufacturing process changes.
• Debt Refinancing: In March 2024, the company entered an Amended and Restated Credit Agreement, refinancing existing debt and incurring $2.7 million in refinancing costs during the nine-month period.

Outlook, Risks, and Contingencies

• Guidance: The company expects to continue incurring net losses for at least the next 12 months. No specific numerical revenue guidance was provided in the text.
• Debt Maturity Risks: The 2025 Convertible Notes ($15.2 million outstanding) mature on July 15, 2025. The 2029 Loans ($200 million facility) have a maturity date that could accelerate to January 15, 2025, if the 2025 Convertible Notes are not redeemed or extended by that date and the company has not raised sufficient equity/debt to redeem them.
• Supply Chain Risks: The company relies on single-source suppliers for key products. Disruptions, particularly those related to geopolitical conflicts (e.g., Israel-Hamas war affecting suppliers in Israel), could impact manufacturing and supply.
• Contingent Value Rights (CVRs): The company settled the 2023 Keveyis milestone in Q1 2024 by issuing shares. The 2023 Recorlev milestone was not achieved. The 2024 Recorlev milestone ($80 million net revenue) remains outstanding.

Investor Verification Checklist

• Debt Redemption Plan: Verify the company's specific strategy to refinance or redeem the $15.2 million 2025 Convertible Notes maturing in July 2025 to avoid acceleration of the $200 million credit facility.
• Recorlev Sustainability: Assess whether the 111% year-over-year revenue growth for Recorlev is sustainable or if it is driven by temporary factors.
• Manufacturing Costs: Monitor future COGS to ensure the $3.6 million Gvoke component write-off was a one-time event and that capacity expansion does not lead to recurring inefficiencies.
• Supply Chain Resilience: Review the status of suppliers in geopolitical hotspots (specifically Israel) and the company's contingency plans for Keveyis and Recorlev production.
• Cash Burn Rate: Confirm that the $39 million net cash used in operating activities for the nine months aligns with the 12-month liquidity runway stated by management.